Harvard Bioscience (HBIO) Return on Equity (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY), and the FY2025 annual result was 0.01%, down 1.0% from the prior year.
• Return on Equity advanced to 0.01% in Q1 2026 per HBIO's latest filing, from 0.04% in the prior quarter.
• Over five years, Return on Equity peaked at 0.0% in Q1 2023 and troughed at 0.04% in Q4 2025.
• A 5-year average of 0.01% and a median of 0.0% in 2022 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2025 and 2026: Return on Equity decreased 4 bps in 2025, then rose 1 bps in 2026.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then soared by 69 bps to 0.0% in 2023, then plunged by 344 bps to 0.0% in 2024, then slumped by 2042 bps to 0.04% in 2025, then jumped by 79 bps to 0.01% in 2026.
• Business Quant data shows HBIO's Return on Equity at 0.01% in Q1 2026, 0.04% in Q4 2025, and 0.04% in Q3 2025.